Tesamorelin: An Approved Peptide With a Narrow Mandate

The short version

Tesamorelin is a synthetic 44-amino-acid analogue of growth-hormone-releasing hormone (GHRH). The body's own GHRH is the signal the hypothalamus sends to the pituitary gland to release growth hormone. Tesamorelin mimics that signal but carries a chemical modification on one end that makes it more resistant to the enzyme that normally breaks GHRH down quickly, giving it a longer active window ^[9][11].

It holds an FDA approval, but a narrow one: reducing excess abdominal fat in HIV-positive adults with lipodystrophy — a side effect of some older antiretroviral drugs that causes fat to accumulate in the abdomen and deplete from the limbs. In five randomized controlled trials in that population, tesamorelin reduced visceral fat and hepatic fat significantly versus placebo ^[8][10][12]. Outside that HIV indication, all uses are off-label and investigational.

The honest caveats: visceral fat reaccumulates when tesamorelin is stopped ^[12]; GH-axis stimulation raises IGF-1 (a growth factor); it is prohibited in sport; and benefits in non-HIV populations — while mechanistically plausible — are not established by large RCTs ^[9]. This page summarizes what was studied — not advice, no human dose.

What it is

Tesamorelin (also known as TH9507) is a synthetic peptide analogue of human growth-hormone-releasing hormone, specifically the 44-amino-acid form GHRH(1-44)-NH2, bearing a trans-3-hexenoic acid group conjugated to the N-terminus. That N-terminal modification is the engineering key: it confers resistance to cleavage by dipeptidyl peptidase-IV (DPP-IV), the enzyme that rapidly inactivates native GHRH. As a result, tesamorelin has a longer effective half-life in plasma than the natural hormone.

Tesamorelin is supplied clinically as the acetate salt. Its empirical formula of the free base is C221H366N72O67S. It is classified as a prescription drug in the jurisdictions where it is approved (United States). Research-grade tesamorelin is also synthesized and sold for laboratory research, but lacks the purity and potency oversight of the approved pharmaceutical product.

How it works

Tesamorelin binds the GHRH receptor (GHRH-R) on somatotroph cells in the anterior pituitary gland, activating the Gs-protein/adenylyl-cyclase/cAMP/PKA signaling cascade. This stimulates the synthesis and pulsatile secretion of endogenous growth hormone. The pulsatile pattern matters: because tesamorelin amplifies the body's own GH-release rhythm rather than supplying steady exogenous GH, its metabolic profile differs from recombinant human growth hormone.

The released GH then drives hepatic production of insulin-like growth factor-1 (IGF-1). Together GH and IGF-1 promote lipolysis — the breakdown of stored fat — preferentially in visceral adipose tissue (the deep belly fat that surrounds organs). In healthy men, a two-week course of tesamorelin 2 mg/day raised mean overnight GH by 0.5 μg/L (P=0.004) and IGF-1 by 181 μg/L (P<0.0001) without significantly affecting insulin sensitivity at that timeframe ^[11]. That latter point — preserved insulin sensitivity — distinguishes tesamorelin from exogenous recombinant GH, which more consistently impairs glucose regulation.

What the research shows

Meta-analytic synthesis. A 2026 meta-analysis pooling five RCTs in HIV-associated lipodystrophy found tesamorelin reduced visceral adipose tissue by a mean of 27.71 cm2 (95% CI −38.37 to −17.06; P<0.001), reduced trunk fat by 1.18 kg, reduced hepatic fat fraction by 4.28%, and increased lean body mass by 1.42 kg — all statistically significant, with no serious adverse events reported ^[8].

JAMA visceral-fat RCT. In 50 antiretroviral-treated HIV adults randomized to tesamorelin 2 mg/day or placebo for six months, the treatment effect on visceral fat was −42 cm2 (P=0.005), and hepatic lipid-to-water percentage fell by a net 2.9% (P=0.003) ^[10].

Long-term sustained effect and rebound. In the 52-week program (273 tesamorelin vs. 137 placebo), VAT reduction was sustained at approximately −18% over the full year versus baseline. Visceral fat reaccumulated upon discontinuation — a key finding that means benefits are contingent on continued dosing ^[12]. Changes in glucose parameters over 52 weeks were not clinically significant.

GH axis and insulin sensitivity. In 13 healthy men over two weeks, tesamorelin raised GH and IGF-1 substantially without significantly affecting fasting glucose or insulin-stimulated glucose uptake, suggesting the GHRH-analogue route does not acutely impair insulin sensitivity at this dose-duration ^[11].

Regulatory and safety profile. The NIH LiverTox monograph assigns tesamorelin a likelihood score of E for drug-induced liver injury — the lowest risk category — with no reported attributable liver-injury cases and no de novo serum-enzyme elevations in trials ^[9].

Reported effects, cautions & safety

Tesamorelin has a defined clinical safety record within the HIV lipodystrophy trials, but several important cautions shape how its evidence should be read:

• Approval is narrow. FDA approval (NDA 022505, November 2010) is specifically for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. All other uses — general visceral-fat reduction in the general population, anti-aging, non-HIV metabolic liver disease, cognitive enhancement — are off-label and investigational ^[9].
• Visceral fat reaccumulates on stopping. Benefits are not durable after discontinuation; fat returns within weeks to months ^[12]. Continued dosing is required to maintain effect.
• HIV-specific trial population. Pivotal efficacy trials were conducted in HIV-positive adults on antiretroviral therapy. Generalizability to non-HIV populations is mechanistically plausible but not established by large RCTs ^[8].
• IGF-1 elevation and oncologic signal. GH-axis stimulation raises serum IGF-1; while trials showed no excess malignancy over 52 weeks, long-term oncologic safety data are limited, and active malignancy is a labeled contraindication ^[9].
• Glucose monitoring warranted in prediabetes. Modest glucose perturbation can occur; monitoring is appropriate in individuals with dysglycemia, though the formal trials found no clinically significant HbA1c changes ^[8].
• Prohibited in sport. Tesamorelin is a GHRH analogue on the WADA Prohibited List (S2: peptide hormones, growth factors, related substances and mimetics), prohibited in- and out-of-competition.
• Research-grade product. Research-grade tesamorelin sold for laboratory use lacks the purity and potency oversight of the approved pharmaceutical.

Tesamorelin has no labeled community-anecdote reports in this desk's source material outside the HIV trial context; cautions above are drawn from the cited literature and the regulatory monograph.

Where it fits in metabolic research

Tesamorelin is the better-evidenced compound on this desk by a wide margin — not because the question it answers is wider, but because it has actually answered a specific question in controlled trials: it reduces visceral fat in HIV lipodystrophy, measurably and repeatedly ^[8][10][12]. What makes it equally instructive is the precision of that mandate. The approval is real, the effect is real, and the limits are real: it is an HIV drug that works via a GH axis, not a general weight-loss drug, and its benefits do not outlast its dosing. Read alongside MOTS-c — which has the metabolic mechanism and the animal data but no human efficacy trials — tesamorelin shows what it takes to move a promising peptide into clinical evidence. See the comparison page for how they line up.